How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
Background
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Items 101–200 of 762
Mason, T., Coelho‐Filho, O. R., Verma, S., Chowdhury, B., Zuo, F., Quan, A., Thorpe, K. E., Bonneau, C., Teoh, H., Gilbert, R. E., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.10.017 · Cited by 111
Self-citationTanaka, A., Hisauchi, I., Taguchi, I., Sezai, A., Toyoda, S., Tomiyama, H., Sata, M., Ueda, S., Oyama, J., Kitakaze, M., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12707 · Cited by 109
Fu, J. M., & Retnakaran, R. R. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101294 · Cited by 108
Packer, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1732 · Cited by 105
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 108
Lan, N. S. R., Fegan, P. G., Yeap, B. B., & Dwivedi, G. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12505 · Cited by 106
“key determinant of HF outcomes according to a recent exploratory analysis of the EMPA-REG OUTCOME trial.(34) It is hy-”
BackgroundMethodvan Raalte, D. H., Bjornstad, P., Persson, F., Powell, D. R., de Cassia Castro, R., Wang, P. S., Liu, M., Heerspink, H. J. L., & Cherney, D. (2019) · Diabetes Care · doi:10.2337/dc19-0937 · Cited by 92
“Sodium–glucose cotransporter (SGLT)2 inhibition–related natriuresis has also been linkedwith improved CV outcomes, as reflected by the association between increased hematocritdas a marker of hemoconcentrationdin the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-…”
BackgroundInfluentialEffects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide
Januzzi, J. L., Xu, J., Li, J., Shaw, W., Oh, R., Pfeifer, M., Butler, J., Sattar, N., Mahaffey, K. W., Neal, B., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.004 · Cited by 97
Packer, M. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.015 · Cited by 95
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
Newman, J. D., Vani, A. K., Aleman, J. O., Weintraub, H. S., Berger, J. S., & Schwartzbard, A. Z. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.071 · Cited by 93
“hematocrit), appeared to have a larger impact on the reduction of CV mortality than measures of glycemia (23).”
BackgroundThe Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Solini, A., Seghieri, M., Giannini, L., Biancalana, E., Parolini, F., Rossi, C., Dardano, A., Taddei, S., Ghiadoni, L., & Bruno, R. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00706 · Cited by 95
Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1096 · Cited by 93
“on CV deaths (19) (Supplementary Appendix,”
Self-citationCardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Postprandial glucose spikes, an important contributor to cardiovascular disease in diabetes?
Hanssen, N. M. J., Kraakman, M. J., Flynn, M. C., Nagareddy, P. R., Schalkwijk, C. G., & Murphy, A. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.570553 · Cited by 90
Ferreira, J. P., Anker, S. D., Butler, J., Filippatos, G. S., Iwata, T., Salsali, A., Zeller, C., Pocock, S., Zannad, F. M., & Packer, M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2409 · Cited by 88
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Verma, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.028 · Cited by 83
Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection
Cherney, D. Z., Odutayo, A., Aronson, R., Ezekowitz, J., & Parker, J. D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.022 · Cited by 81
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Schönberger, E., Mihaljević, V., Steiner, K., Šarić, S., Kurevija, T., Majnarić, L. T., Bilić-Čurčić, I., & Canecki-Varžić, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20176671 · Cited by 93
“Therefore, the antioxidant effect of SGLT2 inhibitors might suggest why a lower uric acid concentration is a significant predictor of this drug-class effect on CV events reduction [88,94,95].”
BackgroundPacker, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa064 · Cited by 86
Liu, H., Sridhar, V. S., Boulet, J., Dharia, A., Khan, A. A., Lawler, P. R., & Cherney, D. Z. I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154918 · Cited by 90
Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13615 · Cited by 85
“compared with a model including treatment group alone, and percentage mediation was calculated as described in Inzucchi et al.(6) Mediation was indicated if the HR for the composite of HHF or HF death between treatment groups adjusted for the covariate was closer to unity than the HR from the model with treatment grou…”
InfluentialSelf-citationKosiborod, M., Birkeland, K. I., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Jørgensen, M. E., Wittbrodt, E. T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13299 · Cited by 82
“As an example, prior analyses from the EMPA-REG OUTCOME trial have demonstrated little mediation effect of HbA1c on the cardiovascular benefits of empagliflozin.(6) Potential mechanisms may involve reductions in oxidative stress, improvement in endothelial function, neuro-hormonal modulation and anti-inflammatory effe…”
ResultInzucchi, S. E., Fitchett, D., Jurišić‐Eržen, D., Woo, V., Hantel, S., Janista, C., Kaspers, S., George, J. T., Zinman, B., & on behalf of the EMPA‐REG OUTCOME® Investigators (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13938 · Cited by 82
Self-citationTamaki, S., Yamada, T., Watanabe, T., Morita, T., Furukawa, Y., Kawasaki, M., Kikuchi, A., Kawai, T., Seo, M., Abe, M., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007048 · Cited by 88
Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial
Andersen, C. F., Omar, M., Glenthøj, A. B., Fassi, D. E., Møller, H. J., Kurtzhals, J. A. L., Styrishave, B., Kistorp, C., Tuxen, C., Poulsen, M. K., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2735 · Cited by 91
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management
Khunti, K., Zaccardi, F., Amod, A., Aroda, V. R., Montoya, P. A., Colagiuri, S., Mohan, V., & Chan, J. C. N. (2024) · Diabetologia · doi:10.1007/s00125-024-06254-w · Cited by 91
Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82
Joubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.003 · Cited by 81
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Chen, X., Hocher, C., Shen, L., Krämer, B. K., & Hocher, B. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00177.2023 · Cited by 84
Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure
Marton, A., Saffari, S. E., Rauh, M., Sun, R.-N., Nagel, A. M., Linz, P. R., Lim, T. T., Takase‐Minegishi, K., Pajarillaga, A., Saw, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.020 · Cited by 88
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
Koshino, A., Schechter, M., Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Rossing, P. R., Correa‐Rotter, R., McMurray, J. J. V., Górriz, J. L., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300049 · Cited by 82
Gullaksen, S., Vernstrøm, L., Sørensen, S. S., Ringgaard, S., Laustsen, C., Funck, K. L., Poulsen, P. L., & Laugesen, E. (2023) · Diabetologia · doi:10.1007/s00125-023-05876-w · Cited by 75
Lingvay, I., Deanfield, J. E., Kahn, S. E., Weeke, P. E., Toplak, H., Scirica, B. M., Rydén, L., Rathor, N., Plutzky, J., Morales, C., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0764 · Cited by 84
Irace, C., Casciaro, F., Scavelli, F. B., Oliverio, R., Cutruzzolà, A., Cortese, C., & Gnasso, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0695-y · Cited by 74
“mediators of the reduction in risk of CV death with empagliflozin vs placebo [27].”
BackgroundPiepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2351 · Cited by 80
Cohen, N. D., Gutman, S., Briganti, E. M., & Taylor, A. J. (2019) · Internal Medicine Journal · doi:10.1111/imj.14260 · Cited by 74
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
Beitelshees, A. L., Leslie, B. R., & Taylor, S. I. (2019) · Diabetes · doi:10.2337/dbi18-0006 · Cited by 78
“EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58 were all designed as randomized placebo-controlled trials.”
BackgroundInfluentialKonig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01386-4 · Cited by 73
“Statistical analysis A mediation analysis approach [18] was used to estimate the degree to which the effect of one or more of the CV risk factors previously found to be favorably affected by dulaglutide could statistically account for its effect on the primary MACE outcome.”
MethodAlicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae212 · Cited by 81
Sharma, A., & Verma, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.003 · Cited by 65
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
Salvatore, T., Caturano, A., Galiero, R., Martino, A. D., Albanese, G., Vetrano, E., Sardu, C., Marfella, R., Rinaldi, L., & Sasso, F. C. (2021) · Biomedicines · doi:10.3390/biomedicines9101356 · Cited by 74
“The inhibition of SGLT2 may attenuate the downstream effects of neurohormonal activation in HF and ameliorate the tissue oxygenation thanks to an increase in hemoglobin and hematocrit levels [146,147].”
BackgroundTamargo, J. L. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.34.2 · Cited by 74
Miyata, K. N., Lo, C., Zhao, S., Liao, M.-C., Pang, Y., Chang, S., Peng, J., Kretzler, M., Filep, J. G., Ingelfinger, J. R., et al. (2021) · Clinical Science · doi:10.1042/cs20210094 · Cited by 73
“It has been suggested that the hematocrit increasing effect of SGLT2i is one of the most important mediators of the reduction in cardiovascular death with SGLT2i versus placebo [61, 62].”
BackgroundMosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 76
Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
Trum, M., Riechel, J., & Wagner, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157976 · Cited by 73
“demonstrated that the reduction in HbA1c levels by empagliflozin contributed only slightly to the observed cardioprotective effects [7].”
BackgroundKetones: the double-edged sword of SGLT2 inhibitors?
Lupsa, B. C., Kibbey, R. G., & Inzucchi, S. E. (2022) · Diabetologia · doi:10.1007/s00125-022-05815-1 · Cited by 76
Self-citationFatima, A., Rasool, S., Devi, S., Talha, M., Waqar, F., Nasir, M. I., Khan, M. R., Jaffari, S. M. I. A., Haider, A., Shah, S. U., et al. (2023) · Cureus · doi:10.7759/cureus.46243 · Cited by 83
“Hemodynamic effects: SGLT2 inhibitors have been shown to reduce blood pressure, arterial stiffness, and preload through natriuresis and osmotic diuresis [21].”
Lauritsen, K. M., Nielsen, B. R. R., Tolbod, L. P., Johannsen, M., Hansen, J., Hansen, T. K., Wiggers, H., Møller, N., Gormsen, L. C., & Søndergaard, E. (2020) · Diabetes · doi:10.2337/db20-0921 · Cited by 70
“Another potential cardioprotective mechanism is through the natriuresis and osmotic diuresis induced by SGLT2 inhibitors (10).”
BackgroundKishimoto, S., Maruhashi, T., Kajikawa, M., Matsui, S., Hashimoto, H., Takaeko, Y., Harada, T., Yamaji, T., Han, Y., Kihara, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68319-1 · Cited by 79
Ferreira, J. P., Inzucchi, S. E., Mattheus, M., Meinicke, T. W., Steubl, D., Wanner, C., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14559 · Cited by 71
“inhibitors improve cardiovascular outcomes also lower UA levels, notably the reduction of oxidative stress.(16) Moreover, through a reduction in UA, a reduction in gout events is of high clinical relevance as gout is the most common form of inflammatory arthritis, may lead”
BackgroundResultSelf-citationWang, C.-C., Li, Y., Qian, X.-Q., Zhao, H., Wang, D., Zuo, G.-X., & Wang, K. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2064479 · Cited by 68
“mortality in patients with diabetes [34].”
Renal physiology of glucose handling and therapeutic implications
Cherney, D. Z. I., Kanbay, M., & Lovshin, J. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz230 · Cited by 73
“Other supportive evidence for a contraction of plasma volume with these agents includes an increase in circulating and urinary levels of RAS hormones, at least in the short term [19, 44, 45], and increases in serum albumin and hematocrit that are thought to reflect hemoconcentration [12].”
BackgroundMethodHerrington, W. G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L. H., Dendale, P., Seferovic, P., Rosano, G., Staplin, N., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2286 · Cited by 63
Fediuk, D. J., Nucci, G., Dawra, V. K., Cutler, D. L., Amin, N. B., Terra, S. G., Boyd, R. A., Krishna, R., & Sahasrabudhe, V. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00875-1 · Cited by 72
Scheen, A. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.008 · Cited by 60
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Wanner, C., & Marx, N. (2018) · Diabetologia · doi:10.1007/s00125-018-4678-z · Cited by 65
Self-citationMechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors
Wójcik, C., & Warden, B. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1219-4 · Cited by 71
Soares, R. N., Ramirez‐Perez, F. I., Cabral-Amador, F. J., Morales‐Quinones, M., Foote, C. A., Ghiarone, T., Sharma, N., Power, G. J., Smith, J. A. H., Rector, R. S., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00563-x · Cited by 67
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
Mayne, K. J., Staplin, N., Keane, D. F., Wanner, C., Brenner, S., Cejka, V., Stegbauer, J., Judge, P. K., Preiss, D., Emberson, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000271 · Cited by 66
Self-citationChawla, G., & Chaudhary, K. K. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.035 · Cited by 69
Xu, C., Ha, X., Yang, S., Tian, X., & Jiang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1232790 · Cited by 69
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 66
Biegus, J., Fudim, M., Salah, H. M., Heerspink, H. J. L., Voors, A. A., & Ponikowski, P. P. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2967 · Cited by 66
“94 In another small, single centre, prospective, randomized study, patients with T2DM and acute HF were randomized to receive empagliflozin or other glucose lowering therapy.”
Palau, P., Amiguet, M., Domínguez, E., Sastre, C., Mollar, A., Seller, J., Pinilla, J. M. G., Larumbe, A., Valle, A., Gómez‐Doblas, J. J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2560 · Cited by 58
Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
Kramer, C. K., & Zinman, B. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-042017-094221 · Cited by 62
Self-citationUjjawal, A., Schreiber, B., & Verma, A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221090001 · Cited by 57
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
Wanner, C., Nangaku, M., Kraus, B. J., Zinman, B., Mattheus, M., Hantel, S., Schumacher, M. C., Ohneberg, K., Schmoor, C., & Inzucchi, S. E. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae032 · Cited by 59
“The first mediation condition, the effect of empagliflozin on the potential mediators, was assessed for all investigated variables as previously reported [17 ].”
BackgroundMethodResultInfluentialSelf-citationdos Santos, D. S., Polidoro, J. Z., Borges, F. A., & Girardi, A. C. C. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00275.2019 · Cited by 62
Hyperuricemia: a novel old disorder—relationship and potential mechanisms in heart failure
Borghi, C., Palazzuoli, A., Landolfo, M., & Cosentino, E. R. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09869-z · Cited by 61
van Ruiten, C. C., Smits, M. M., Kok, M. D., Serné, E. H., van Raalte, D. H., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01492-x · Cited by 55
“SGLT2i may induce plasma volume contraction, leading to reductions in cardiac pre- and after-load [6].”
BackgroundNephroprotective effects of GLP-1 receptor agonists: where do we stand?
Mosterd, C. M., Bjornstad, P., & van Raalte, D. H. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00738-9 · Cited by 56
Abraham, W. T., Ponikowski, P. P., Brueckmann, M., Zeller, C., Macesic, H., Peil, B., Brun, M., Ustyugova, A., Jamal, W., Salsali, A., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1486 · Cited by 61
Patorno, E., Pawar, A. M., Wexler, D. J., Glynn, R. J., Bessette, L. G., Paik, J. M., Najafzadeh, M., Brodovicz, K. G., Déruaz‐Luyet, A., & Schneeweiß, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14593 · Cited by 62
“It has been suggested that haemodynamic changes in haematocrit and haemoglobin related to plasma volume contraction driven by empagliflozin, which manifested as early as 12 weeks after empagliflozin initiation in the EMPA-REG OUTCOME trial, may be an important mediator of the reduction in cardiovascular mortality risk…”
BackgroundCeriello, A., Lucisano, G., Prattichizzo, F., Grotta, R. L., Frigé, C., Cosmo, S. D., Bartolo, P. D., Cianni, G. D., Fioretto, P., Giorda, C. B., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100666 · Cited by 63
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink
Sattar, N., & McGuire, D. K. (2018) · Circulation · doi:10.1161/circulationaha.118.035083 · Cited by 53
Tsai, W.-C., Hsu, S.-P., Chiu, Y.-L., Yang, J.-Y., Pai, M.-F., Ko, M.-J., Tu, Y.-K., Hung, K.-Y., Chien, K.-L., Peng, Y.-S., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060655 · Cited by 53
Tian, Q., Guo, K., Deng, J., Zhong, Y., & Yang, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17115 · Cited by 56
Fawzy, A. M., Rivera‐Caravaca, J. M., Underhill, P., Fauchier, L., & Lip, G. Y. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14854 · Cited by 52
“In secondary analyses of the EMPA-REG-OUTCOME trial and the CANVAS program, changes in markers associated with plasma volume such as haemoglobin, haematocrit and amino-terminal pro–B-type natriuretic peptide (NT-pro BNP) were the most significant mediators of cardiovascular mortality and heart failure hospitalizations…”
MethodZhao, Z., Jiang, C., He, L., Zheng, S., Wang, Y., Gao, M., Lai, Y., Zhang, J., Li, M., Dai, W., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031269 · Cited by 55
Jensen, J., Omar, M., Kistorp, C., Poulsen, M. K., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Fosbøl, E. L., Bruun, N. E., et al. (2019) · Trials · doi:10.1186/s13063-019-3474-5 · Cited by 55
Nakagawa, Y., & Kuwahara, K. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.03.009 · Cited by 54
Aguilar-Gallardo, J. S., Correa, A. A., & Contreras, J. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab056 · Cited by 54
Renal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 54
Avogaro, A., Fadini, G. P., & Del Prato, S. (2020) · Diabetes Care · doi:10.2337/dc19-1410 · Cited by 51
“increased hematocrit (9), improved sodium concentration in cardiomyocytes (10), and many more.”
BackgroundAberle, J., Menzen, M., Schmid, S. M., Terkamp, C., Jaeckel, E., Rohwedder, K., Scheerer, M. F., Xu, J. L., Tang, W., & Birkenfeld, A. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-78734-z · Cited by 53
Correction of anemia by dapagliflozin in patients with type 2 diabetes
Stefánsson, B. V., Heerspink, H. J. L., Wheeler, D. C., Sjöström, C. D., Greasley, P. J., Sartipy, P., Cain, V. A., & Correa‐Rotter, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107729 · Cited by 54
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48
“The smart diuretic hypothesis [51] suggests that the cardiorenal benefits observed with SGLT-2i are in part due to their more selective diuretic effects, leading to osmotic diuresis.”
BackgroundLi, M., Yi, T., Fan, F., Qiu, L., Wang, Z., Weng, H., Ma, W., Zhang, Y., & Huo, Y. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01574-w · Cited by 52
“The results of the EMPA-REG OUTCOME trial indicated that changes in hematocrit, which are ostensibly a marker of the effects of the drug on volume, appeared to be an important mediator of the reduction in mortality risk [47].”
ResultBonora, B. M., Cappellari, R., Albiero, M., Avogaro, A., & Fadini, G. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00824 · Cited by 51
“reanalysis of the EMPA-REG Outcome trial (29), change from baseline in hematocrit mediated.”
Hussein, H., Zaccardi, F., Khunti, K., Seidu, S., Davies, M. J., & Gray, L. J. (2019) · Diabetic Medicine · doi:10.1111/dme.13898 · Cited by 43
Chung, M., Hung, P., Hsiao, P., Wu, L.-Y., Chang, C., Wu, M., Shieh, J., & Chung, C. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.35353 · Cited by 51
Inzucchi, S. E., Khunti, K., FITCHETT, D. H., Wanner, C., Mattheus, M., George, J. T., Ofstad, A. P., & Zinman, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa321 · Cited by 50
“This leads to reductions in plasma volume (60), increases in hematocrit (61), and decreases in arterial stiffness and vascular resistance (62).”
BackgroundMethodSelf-citationVerma, S., Ji, Q., Bhatt, D. L., Mazer, C. D., Al-Omran, M. A., Inzucchi, S. E., Wanner, C., Ofstad, A. P., Zwiener, I., George, J. T., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13991 · Cited by 46
“Empagliflozin consistently reduced these outcomes across the range of baseline uric acid levels, and this observation supports the mediation analysis undertaken in EMPAREG OUTCOME, demonstrating that changes in uric acid mediated ~20% to 25% of the reduction in CV death and HHF or HF death seen with empagliflozin.(10,…”
Self-citationSGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
Muric, M. D., Zivkovic, V. I., Joksimović, J., Sretenovic, J. Z., Davidović, G., Simovic, S. M., Djoković, D., Muric, N. N., Bolevich, S., & Jakovljevic, V. L. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10079-9 · Cited by 49
Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109927 · Cited by 48
The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
Tsampasian, V., Baral, R., Chattopadhyay, R. K., Dębski, M., Joshi, S. S., Reinhold, J., Dweck, M. R., Garg, P., & Vassiliou, V. S. (2021) · Cardiology Research and Practice · doi:10.1155/2021/9927533 · Cited by 51
“Additionally, the activation of SIRT1 leads to stimulation of erythropoietin synthesis and erythrocytosis, which has been found to be one of the factors contributing to the significant cardiovascular benefits of SGLT2 inhibitors [31, 32].”
BackgroundEmpagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects
Rao, V. S., Ivey-Miranda, J. B., Cox, Z. L., Moreno-Villagómez, J., Maulion, C., Bellumkonda, L., Chang, J. J., Field, M. P., Wiederin, D. R., Butler, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000269 · Cited by 48
Self-citationSavarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.